Eton Licenses U.S. Rights to LIBERVANT for $10M Upfront
Eton Pharmaceuticals entered two agreements with Aquestive Therapeutics for exclusive U.S. commercialization rights to LIBERVANT, a diazepam buccal film for epilepsy, subject to FDA approvals. The deal includes $10 million upfront plus milestones.